• Bayer completed its acquisition of Perfuse Therapeutics, fully integrating the company.
• Deal secures full rights to PER-001 intravitreal implant, a Phase II sustained-release endothelin receptor antagonist for glaucoma and diabetic retinopathy.
• Bayer paid an upfront USD 300 million; total potential value up to USD 2.45 billion including success-based milestones.
• Transaction strengthens Bayer’s ophthalmology pipeline, leveraging its existing footprint in the specialty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202606170230BIZWIRE_USPR_____20260616_BW791003) on June 17, 2026, and is solely responsible for the information contained therein.